NEW YORK - Merck & Co Inc cut its sales outlook on two key medicines on Monday and indicated its financial forecasts were in doubt after a mostly negative study of cholesterol treatment Vytorin, sending its shares down 7 percent.
This entry was posted
on Monday, July 21st, 2008 at 11:42 pm and is filed under General Business.
You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.